Advertisement

Repeat re-irradiation with interstitial HDR-brachytherapy for an in-field isolated nodal recurrence in a patient with HPV-positive squamous cell carcinoma of the head and neck

Published:December 31, 2022DOI:https://doi.org/10.1016/j.brachy.2022.12.003

      Abstract

      PURPOSE

      Locoregionally recurrent head and neck cancer is a complex clinical scenario that often requires multimodality treatment. These patients have often previously received definitive treatment with a combination of surgery, radiation therapy, and systemic therapy, which can make further management difficult. A second isolated locoregional failure is rare and clinicians are faced with a challenge to optimize disease control while minimizing treatment-related toxicity.

      METHODS AND MATERIALS

      In this report, we present the diagnosis, management, and outcomes of a patient with an isolated locoregional recurrence who was previously treated with two courses of radiation. The patient was treated with a second course of reirradiation using interstitial brachytherapy as well as a discussion regarding patient selection and optimal management for recurrent head and neck cancer.

      RESULTS

      Repeat reirradiation using interstitial HDR-brachytherapy with the use of an alloderm spacer was successfully delivered to the patient for an in-field right neck nodal recurrence. He received a total EQD2/BED dose of 127.70/153.24 Gy. At 1-year followup, the patient was without evidence of recurrent disease or new significant side effects.

      CONCLUSION

      Recurrent head and neck cancer should be managed with a multidisciplinary approach given the complex clinical scenario. Reirradiation is a commonly used salvage measure for recurrent head and neck cancer that requires careful planning and patient selection due to prior treatment-related effects and dose constraints. We reported a case of a second course of reirradiation using interstitial HDR-brachytherapy for locoregionally recurrent head and neck cancer and showed no recurrence of disease or worsening long term side effects at 1 year.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • von der Grun J.
        • et al.
        Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max ) of >180 Gy for patients with recurrent head and neck cancer.
        Head Neck. 2019; 41: E48-E54
        • Ward M.C.
        • et al.
        Retreatment of recurrent or second primary head and neck cancer after prior radiation: executive summary of the American radium society appropriate use criteria.
        Int J Radiat Oncol*Biol*Phys. 2022; 113: 759-786
        • Zafereo M.E.
        • et al.
        The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx.
        Cancer. 2009; 115: 5723-5733
        • Agra I.M.
        • et al.
        Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer.
        Head Neck. 2006; 28: 107-113
        • Vargo J.A.
        • et al.
        A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer.
        Int J Radiat Oncol Biol Phys. 2018; 100: 595-605
        • Kreinbrink P.J.
        • et al.
        Reirradiation of recurrent and second primary cancers of the head and neck: a review of the contemporary evidence.
        Curr Treat Options Oncol. 2022; 23: 295-310
        • Tagliaferri L.
        • et al.
        Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: single-institution experience and systematic review.
        Tumori. 2017; 103: 516-524
        • Chen A.M.
        • et al.
        Tolerance of the brachial plexus to high-dose reirradiation.
        Int J Radiat Oncol Biol Phys. 2017; 98: 83-90
        • Dibs K.
        • et al.
        Brachial plexus tolerance to high-dose radiation in the re-irradiation setting.
        Int J Radiat Oncol*Biol*Phys. 2021; 111: e240-e241
        • Dionisi F.
        • et al.
        Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: a literature review.
        Oral Oncol. 2019; 98: 35-47
        • Chopra S.
        • et al.
        Re-irradiation in the management of isolated neck recurrences: current status and recommendations.
        Radiother Oncol. 2006; 81: 1-8
        • Kowalski L.P.
        Results of salvage treatment of the neck in patients with oral cancer.
        Arch Otolaryngol Head Neck Surg. 2002; 128: 58-62
        • Wong L.Y.
        • et al.
        Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery.
        Head Neck. 2003; 25: 953-959
        • Clancy K.
        • et al.
        Outcomes of microvascular free tissue transfer in twice-irradiated patients.
        Microsurgery. 2017; 37: 574-580
        • Cohn A.B.
        • et al.
        Free-flap reconstruction in the doubly irradiated patient population.
        Plast Reconstr Surg. 2008; 122: 125-132
        • Ho A.S.
        • et al.
        Impact of flap reconstruction on radiotoxicity after salvage surgery and reirradiation for recurrent head and neck cancer.
        Ann Surg Oncol. 2016; 23: 850-857
        • Janot F.
        • et al.
        Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
        J Clin Oncol. 2008; 26: 5518-5523
        • Ward M.C.
        • et al.
        Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: a multi-institution cohort study by the MIRI collaborative.
        Int J Radiat Oncol Biol Phys. 2018; 100: 586-594
        • Vargo J.A.
        • et al.
        Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
        Laryngoscope. 2014; 124: 1579-1584
        • Vargo J.A.
        • et al.
        Head and neck tumor control probability: radiation dose-volume effects in stereotactic body radiation therapy for locally recurrent previously-irradiated head and neck cancer: report of the AAPM Working Group.
        Int J Radiat Oncol Biol Phys. 2021; 110: 137-146
        • Martínez-Monge R.
        • et al.
        Perioperative high-dose-rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: initial results of a Phase I/II reirradiation study.
        Brachytherapy. 2006; 5: 32-40
        • Bollet M.A.
        • et al.
        Cervical lymph node relapses of head-and-neck squamous cell carcinoma: is brachytherapy a therapeutic option?.
        Int J Radiat Oncol Biol Phys. 2001; 51: 1305-1312
        • Puthawala A.
        • et al.
        Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results.
        Int J Radiat Oncol Biol Phys. 2001; 51: 354-362
        • Breen W.
        • et al.
        Permanent interstitial brachytherapy for previously irradiated head and neck cancer.
        Cureus. 2018; 10: e2517
        • Perry D.J.
        • et al.
        High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer.
        Int J Radiat Oncol Biol Phys. 2010; 76: 1140-1146
        • Martínez-Fernández M.I.
        • et al.
        Perioperative high dose rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: results of a phase I/II reirradiation study.
        Radiother Oncol. 2017; 122: 255-259
        • Rudžianskas V.
        • et al.
        Reirradiation for patients with recurrence head and neck squamous cell carcinoma: a single-institution comparative study.
        Medicina (Kaunas). 2014; 50: 92-99
        • Kharouta M.
        • et al.
        Permanent interstitial cesium-131 brachytherapy in treating high-risk recurrent head and neck cancer: a prospective pilot study.
        Front Oncol. 2021; 11639480
        • Khan N.
        • et al.
        The role of salvage surgery with interstitial brachytherapy for the management of regionally recurrent head and neck cancers.
        Cancers Head Neck. 2019; 4: 4
        • Monnier L.
        • et al.
        Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
        Head Neck. 2013; 35: 1683-1688
        • Nguyen N.T.
        • et al.
        0-7-21 hypofractionated palliative radiotherapy: an effective treatment for advanced head and neck cancers.
        Br J Radiol. 2015; 8820140646
        • Agarwal J.P.
        • et al.
        Hypofractionated, palliative radiotherapy for advanced head and neck cancer.
        Radiother Oncol. 2008; 89: 51-56
        • Corry J.
        • et al.
        The 'QUAD SHOT'–a phase II study of palliative radiotherapy for incurable head and neck cancer.
        Radiother Oncol. 2005; 77: 137-142
        • Paris K.J.
        • et al.
        Phase I-II study of multiple daily fractions for palliation of advanced head and neck malignancies.
        Int J Radiat Oncol Biol Phys. 1993; 25: 657-660
        • Gamez M.E.
        • et al.
        Hypofractionated palliative radiotherapy with concurrent radiosensitizing chemotherapy for advanced head and neck cancer using the "QUAD-SHOT Regimen".
        Anticancer Res. 2017; 37: 685-691
        • Fan D.
        • et al.
        Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.
        Oral Oncol. 2020; 104104641
        • Alterio D.
        • et al.
        Carotid blowout syndrome after reirradiation for head and neck malignancies: a comprehensive systematic review for a pragmatic multidisciplinary approach.
        Crit Rev Oncol Hematol. 2020; 155103088
        • Spencer S.A.
        • et al.
        Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
        Head Neck. 2008; 30: 281-288
        • Langer C.J.
        • et al.
        Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
        J Clin Oncol. 2007; 25: 4800-4805
      1. Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma. Available at: https://clinicaltrials.gov/ct2/show/NCT04671667, Accessed on October 20, 2022.

      2. SBRT +/- Pembrolizumab in patients with local-regionally recurrent or second primary head and neck carcinoma (KEYSTROKE). Available at: https://clinicaltrials.gov/ct2/show/NCT03546582, Accessed on October 20, 2022.